Fazio, Nicola <br/><br/>
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.  [electronic resource] 

 -  Anticancer research  Feb 2016 
 - 713-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1791-7530 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Drug Administration Schedule<br/>Drug Resistance, Neoplasm<br/>Everolimus--therapeutic use<br/>Female<br/>Humans<br/>Imidazoles--administration & dosage<br/>Male<br/>Middle Aged<br/>Neuroendocrine Tumors--drug therapy<br/>Pancreatic Neoplasms--drug therapy<br/>Phosphatidylinositol 3-Kinase--metabolism<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Prospective Studies<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinolines--administration & dosage<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Time Factors<br/>Treatment Outcome